



# Classic Psychedelic Use and Current Meditation Practice

Charlotta Simonsson<sup>1</sup> · Richard Chambers<sup>2</sup> · Peter S. Hendricks<sup>3</sup> · Simon B. Goldberg<sup>4,5</sup> · Walter Osika<sup>6</sup> · Marco Schlosser<sup>7,8</sup> · Adam Ryde<sup>9</sup> · Emma Christersson<sup>10</sup> · Otto Simonsson<sup>6,11</sup>

Accepted: 2 March 2023 / Published online: 29 March 2023

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023

## Abstract

**Objectives** Previous research has investigated potential synergies between classic psychedelics and meditation practice, but relatively little remains known about the relationship between classic psychedelic experiences and engagement with meditation practice. The purpose of this study was to investigate associations between classic psychedelic experiences and engagement with two popular types of meditation: mindfulness meditation and loving-kindness or compassion meditation.

**Method** This retrospective, population-based observational study included 2822 respondents aged 18 years or older in the United States. Using covariate-adjusted regression models, this study examined associations of classic psychedelic experiences with current practice of mindfulness meditation and loving-kindness or compassion meditation.

**Results** In covariate-adjusted regression models, lifetime classic psychedelic use was associated with a higher frequency of current mindfulness meditation practice but not current loving-kindness or compassion meditation practice. Both psychological insight and “ego dissolution” were associated with a higher frequency of current mindfulness meditation practice and current loving-kindness or compassion meditation practice. Notably, when psychological insight and “ego dissolution” were entered into the regression model simultaneously, only greater psychological insight was associated with having a higher frequency of current mindfulness meditation practice and current loving-kindness or compassion meditation practice.

**Conclusions** Although the findings in this study cannot demonstrate causality, they suggest that classic psychedelic experiences may exert a positive effect on the cultivation and maintenance of health-related behaviors such as regular meditation practice, with psychological insight appearing to be a stronger predictor than “ego dissolution.”

**Preregistration** This study was not preregistered.

**Keywords** Psychedelics · Psilocybin · LSD · Meditation · Mindfulness

Classic psychedelics include N,N-dimethyltryptamine (DMT), ayahuasca, lysergic acid diethylamide (LSD), mescaline, the mescaline-containing cacti peyote and San Pedro,

and psilocybin (Sexton et al., 2019). These compounds exert effects through serotonin 2A receptor agonist activity (Carhart-Harris, 2019), appear safe in clinical trials (Dos

✉ Charlotta Simonsson  
char.simonsson@gmail.com

<sup>1</sup> Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden

<sup>2</sup> Monash Centre for Consciousness & Contemplative Studies, Monash University, Melbourne, Australia

<sup>3</sup> Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA

<sup>4</sup> Center for Healthy Minds, University of Wisconsin - Madison, Madison, WI, USA

<sup>5</sup> Department of Counseling Psychology, University of Wisconsin - Madison, Madison, WI, USA

<sup>6</sup> Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden

<sup>7</sup> Division of Psychiatry, Faculty of Brain Sciences, University College London, London, UK

<sup>8</sup> Department of Psychology, Faculty of Psychology and Educational Sciences, University of Geneva, Geneva, Switzerland

<sup>9</sup> Department of Psychiatry, University of Oxford, Oxford, UK

<sup>10</sup> Osmond Foundation, Stockholm, Sweden

<sup>11</sup> Department of Sociology, University of Oxford, Oxford, UK

Santos et al., 2018; see also Schlag et al., 2022, for potential risks), and may be effective in the treatment of various psychiatric disorders when administered in conjunction with therapy (e.g., Bogenschutz et al., 2022; Carhart-Harris et al., 2021). Recent evidence suggests that “ego dissolution” (i.e., reduced self-focus; Nour et al., 2016; Uthaug et al., 2018), psychological insight (i.e., realizations about one’s relationships, personality, or behavioral patterns; Davis et al., 2021), and other constructs related to the quality of acute classic psychedelic experiences may be important for mental health outcomes (Barrett et al., 2015; Peill et al., 2022).

Previous work has identified potential synergies between classic psychedelics and meditation practice (Griffiths et al., 2018; Smigielski et al., 2019). For example, in a cross-sectional study with a nationally representative sample of the US adult population, greater “ego dissolution” — as measured by the highest loading item from the Ego Dissolution Inventory (Nour et al., 2016) — during respondents’ most intense classic psychedelic experience was associated with having tried meditation and, among meditators, having lower perceived barriers to meditation practice and a more frequent meditation practice (Simonsson & Goldberg, 2022). The study did not, however, investigate relationships with classic psychedelic-associated psychological insight, which has been linked to other types of health behavior (e.g., diet, exercise) in prior research (Simonsson et al., 2022). It is possible that psychological insight could lead to greater awareness of helpful and unhelpful behavioral patterns in day-to-day life. Such experiences could potentially facilitate engagement with meditation practice, especially for meditators who have experienced barriers to their meditation practice or who may not have prioritized a regular meditation practice. If such a relationship exists, to better understand mechanisms of action, it would be important to compare the relative strength of psychological insight and “ego dissolution” as predictors of meditation practice.

Using a large, nationally representative sample of the US adult population with regard to sex, age, and ethnicity, we aimed to contribute to this nascent field by investigating the associations between classic psychedelic experiences and engagement with two popular types of meditation practice: mindfulness meditation and loving-kindness or compassion meditation. We hypothesized that greater psychological insight during respondents’ most insightful classic psychedelic experience would be associated with greater frequency of current mindfulness meditation practice and current loving-kindness or compassion meditation practice. We also conducted an exploratory analysis to investigate the relative strength of psychological insight and “ego dissolution” as predictors of meditation practice.

## Method

### Participants

The sample size was determined using GPower (Faul et al., 2007). The analysis (linear multiple regression, fixed model, R<sup>2</sup> increase) revealed that 395 lifetime classic psychedelic users would achieve 80% power to detect small effect sizes with an alpha of 0.05. Assuming similar prevalence of lifetime classic psychedelic use in the US adult population as recent investigations (~14%; Simonsson et al., 2021b), we estimated that 2800 total participants would be necessary to recruit approximately 395 lifetime classic psychedelic users in the sample. We therefore aimed to recruit 2800 participants.

In total, 2822 respondents (18 years or older) were recruited in October 2021 through Prolific Academic (<https://app.prolific.co>). Using Prolific Academic’s representativeness function, the sample was stratified across three demographics — sex, age, and ethnicity — to reflect the demographic distribution of the US adult population.

### Procedure

The respondents were asked to complete questions related to demographic characteristics, substance use, classic psychedelic use, and meditation practice. Study procedures were approved by the Institutional Review Board at the University of Wisconsin—Madison. Respondents who completed the study received a US\$2.20 reimbursement payment.

### Measures

#### Demographics and Substance Use

All respondents were asked to report age in years, gender, educational attainment, lifetime use of cocaine, and alcohol-related risk behavior (as measured by the 3-item Alcohol Use Disorders Identification Test – Concise; Bradley et al., 2007).

#### Classic Psychedelic Use

All respondents were asked to report which, if any, of the following classic psychedelics they had ever used: DMT, ayahuasca, LSD, mescaline, peyote, San Pedro, and psilocybin. Respondents who reported using any of these were coded as positive for lifetime classic psychedelic use, whereas those indicating that they had never used any of these substances were coded as negative (0 = *No*, 1 = *Yes*). Those respondents who reported lifetime classic psychedelic use ( $n = 613$ ) were also asked to complete the Psychological Insight

Questionnaire (Davis et al., 2021), which aims to capture the acute psychologically insightful experiences that can arise during classic psychedelic experiences. The original instructions published by Davis et al. (2021) were adapted in order to ask participants about the experiences that occurred during the most insightful classic psychedelic experience of their life. The questionnaire comprises 23 items with a 6-point Likert scale anchored at 0 (*No; not at all*) and 5 (*Extreme [more than ever before in my life]*). Total scores are derived by averaging the 23-item scores. Higher total scores reflect higher levels of psychological insight. Internal consistency in the current sample was excellent (Cronbach's  $\alpha=0.98$  and McDonald's  $\omega=0.98$ ). Those respondents who reported lifetime classic psychedelic use were also asked to complete the Ego Dissolution Inventory (Nour et al., 2016), with 8 items designed to capture reduced self-focus (e.g., “I experienced a dissolution of my ‘self’ or ego”, “I felt at one with the universe”). The original instructions published by Nour et al. (2016) were adapted in order to ask participants about the experiences that occurred during the most intense classic psychedelic experience of their life. The items were rated on a scale from 0 to 100 (0 = *No, not more than usually*, 100 = *Yes, entirely or completely*). Higher total scores reflect higher levels of “ego dissolution.” Internal consistency in the current sample was excellent (Cronbach's  $\alpha=0.91$  and McDonald's  $\omega=0.91$ ).

### Meditation Practice

All respondents were asked to report if they had ever tried any form of meditation. If respondents reported past meditation use, they were asked whether they had ever tried mindfulness meditation, including Vipassana, Zen Buddhist meditation, Mindfulness-Based Stress Reduction, and Mindfulness-Based Cognitive Therapy. Those respondents who responded positively were asked to estimate how many days per week, on average, over the past 30 days they engaged

with mindfulness meditation (0–7). No experience of mindfulness meditation was coded as 0. If respondents reported past meditation use, they were also asked whether they had ever tried loving-kindness or compassion meditation, including Metta, Compassion Cultivation Training, and Cognitively-Based Compassion Training. Those respondents who responded positively were asked to estimate how many days per week, on average, over the past 30 days they engaged with loving-kindness or compassion meditation (0–7). No experience of loving-kindness or compassion meditation was coded as 0.

### Data Analyses

To evaluate the associations between classic psychedelic use and current meditation practice, we used linear regression models. In these models, lifetime classic psychedelic use, psychological insight (z-scored), and “ego dissolution” (z-scored) were entered as the independent variables while current meditation practice variables were entered as the dependent variables. In line with previous research on classic psychedelics and meditation (Simonsson & Goldberg, 2022), all analyses were adjusted for age in years (18–25, 26–34, 35–49, 50–64, or 65 or older), gender (male, female, transgender/non-binary), educational attainment (some high school or less, high school graduate or equivalent, some college/community college degree, Bachelor's degree or higher), lifetime use of cocaine (yes, no), and problematic alcohol use (continuous).

### Results

Table 1 shows results from the regression models testing the associations between classic psychedelic use and current meditation practice. As shown in the table, lifetime classic psychedelic use was associated with a higher frequency of

**Table 1** Classic psychedelic use and current meditation practice

|                                  | Mindfulness |       |      | Loving-kindness or compassion |       |      |
|----------------------------------|-------------|-------|------|-------------------------------|-------|------|
|                                  | $\beta$     | $p$   | $n$  | $\beta$                       | $p$   | $n$  |
| Model 1                          |             |       |      |                               |       |      |
| Lifetime classic psychedelic use | 0.13        | <0.01 | 2822 | 0.02                          | 0.38  | 2822 |
| Psychological insight            | 0.26        | <0.01 | 613  | 0.25                          | <0.01 | 613  |
| “Ego dissolution”                | 0.12        | <0.01 | 613  | 0.12                          | <0.01 | 613  |
| Model 2                          |             |       |      |                               |       |      |
| Psychological insight            | 0.30        | <0.01 | 613  | 0.26                          | <0.01 | 613  |
| “Ego dissolution”                | −0.05       | 0.28  | 613  | −0.03                         | 0.62  | 613  |

$\beta$ , standardized coefficients. All analyses have been adjusted for age in years, gender, educational attainment, lifetime use of cocaine, and problematic alcohol use. Lifetime classic psychedelic use, psychological insight, and “ego dissolution” were entered into Model 1 separately. Psychological insight and “ego dissolution” were entered into Model 2 simultaneously

current mindfulness meditation practice but was not associated with current loving-kindness or compassion meditation practice. Greater psychological insight during respondents' most insightful classic psychedelic experience was associated with a higher frequency of current mindfulness meditation practice and current loving-kindness or compassion meditation practice. Greater "ego dissolution" during respondents' most intense classic psychedelic experience was associated with a higher frequency of current mindfulness meditation practice and current loving-kindness or compassion meditation practice. Notably, when psychological insight and "ego dissolution" were entered into the regression model simultaneously, only greater psychological insight was associated with having a higher frequency of current mindfulness meditation practice and current loving-kindness or compassion meditation practice, with effects moderate in size.

## Discussion

This study sought to examine the associations between classic psychedelic use and current meditation practice in a representative sample of the US adult population with regard to sex, age, and ethnicity. The results showed that lifetime classic psychedelic use was associated with a slightly higher frequency of current mindfulness meditation practice but not current loving-kindness or compassion meditation practice. Both psychological insight and "ego dissolution" during respondents' most insightful and intense classic psychedelic experiences were associated with a higher frequency of current mindfulness meditation practice and current loving-kindness or compassion meditation practice, though effects were larger for psychological insight than "ego dissolution." Notably, when psychological insight and "ego dissolution" were entered into the regression model simultaneously, only greater psychological insight was associated with having a higher frequency of current mindfulness meditation practice and current loving-kindness or compassion meditation practice, with effects moderate in size.

Although the findings in this study cannot demonstrate causality, they suggest that classic psychedelic experiences may exert a positive effect on the cultivation and maintenance of regular meditation practice. If classic psychedelic experiences can indeed influence meditation practice, it could have important implications for research on both meditation and classic psychedelics. It is possible, for example, that administration of classic psychedelics could increase motivation for meditation practice and thereby reduce attrition rates in meditation-based interventions. It is also possible that meditation practice may prove a valuable adjunct to support integration of the classic psychedelic experience (Payne et al., 2021). Mindfulness and

loving-kindness or compassion meditation techniques may be promising candidates for this purpose, given the substantial body of evidence suggesting these techniques in particular may confer psychological benefits generally (Galante et al., 2014; Goldberg et al., 2022) and share phenomenological and neurophysiological similarities with classic psychedelics (e.g., sense of connection with others, present-moment awareness; Heuschkel & Kuypers, 2020; Pots & Chakhssi, 2022).

## Limitations and Future Directions

The present study has several limitations worthy of consideration when interpreting the overall results. First, due to the cross-sectional design, a cause-and-effect relationship between classic psychedelic-related variables and current meditation practice variables cannot be established. It is, for example, possible that those who engage in meditation tend to experience greater psychological insight during classic psychedelic experiences (or that an unmeasured variable such as absorption explains the relationship). Second, although our models used *lifetime* classic psychedelic use to predict *current* meditation, it is still entirely possible that meditation practice preceded classic psychedelic use (or that a reciprocal relationship exists between these variables). Third, the sample was stratified only across sex, age, and ethnicity to reflect the US adult population. The sample might not have been representative on other variables that may be related to meditation use (e.g., socioeconomic status, political affiliation, sexual orientation; Simonsson et al., 2020, 2021a). Fourth, the retrospective component of the questionnaire may be susceptible to recall bias, which means that responses about past use of classic psychedelics or meditation may have been inaccurate. The use of a single measurement method in this study may also have produced additional biases (Podsakoff et al., 2012). Fifth, the questionnaire did not include information about set and setting related to classic psychedelic use, which are known to influence the effects of classic psychedelics (Carhart-Harris et al., 2018). Sixth, the introduction to the psychological insight and "ego dissolution" measures differed slightly (i.e., most insightful versus most intense), which may have influenced the results. Lastly, we recommend that future research in this area utilize a more comprehensive assessment of meditation practice to further differentiate distinct practices and mechanisms (e.g., Dahl et al., 2015; Schlosser et al., 2022) and their relationships with classic psychedelic use. Future research should also utilize longitudinal designs to explore the potential cause-and-effect relationships between classic psychedelic use and current meditation practice.



**Author Contribution** Charlotta Simonsson: writing — original draft. Richard Chambers: funding acquisition; writing — review and editing. Peter S. Hendricks: conceptualization; funding acquisition; methodology; supervision; writing — review and editing. Simon B. Goldberg: conceptualization; funding acquisition; methodology; supervision; writing — review and editing. Walter Osika: conceptualization; funding acquisition; methodology; supervision; writing — review and editing. Marco Schlosser: writing — review and editing. Adam Ryde: writing — review and editing. Emma Christersson: writing — review and editing. Otto Simonsson: conceptualization; data curation; formal analysis; funding acquisition; investigation; methodology; project administration; supervision; writing — review and editing.

**Funding** OS was supported by the Osmond Foundation and Ekhaga Foundation. SG was supported by a grant (K23AT010879) from the National Center for Complementary and Integrative Health. Support for this research was also provided by FORMAS, Swedish Research Council for Sustainable Development (grant number: FR-2018/0006), Three Springs Foundation through the Monash Centre for Consciousness & Contemplative Studies, the University of Alabama at Birmingham School of Public Health, and the University of Wisconsin—Madison Office of the Vice Chancellor for Research and Graduate Education with funding from the Wisconsin Alumni Research Foundation and with funding from the Wisconsin Center for Education Research.

**Data Availability** The data and Stata syntax are available at Figshare: <https://doi.org/10.6084/m9.figshare.22099673.v1> [Data] and <https://doi.org/10.6084/m9.figshare.22092968.v1> [Syntax].

## Declarations

**Ethical Approval** All procedures performed involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Study procedures were determined to be exempt from review by the Institutional Review Board at the University of Wisconsin—Madison.

**Informed Consent** Informed consent was obtained from all individual participants included in the studies.

**Conflict of Interest** PSH is on the scientific advisory board of Bright Minds Biosciences Ltd., Eleusis Benefit Corporation, and Reset Pharmaceuticals Inc. EC is a board member of Osmond Foundation. OS and RC are co-founders of Eudelics AB. The remaining authors have nothing to disclose.

## References

Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. *Journal of Psychopharmacology*, 29(11), 1182–1190. <https://doi.org/10.1177/0269881115609019>

Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennega, S. E., O'Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, S. J., & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. *JAMA Psychiatry*, 79(10), 953–962. <https://doi.org/10.1001/jamapsychiatry.2022.2096>

Bradley, K. A., DeBenedetti, A. F., Volk, R. J., Williams, E. C., Frank, D., & Kivlahan, D. R. (2007). AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcoholism: Clinical and Experimental Research*, 31(7), 1208–1217. <https://doi.org/10.1111/j.1530-0277.2007.00403.x>

Carhart-Harris, R. L. (2019). How do psychedelics work? *Current Opinion in Psychiatry*, 32(1), 16–21. <https://doi.org/10.1097/YCO.0000000000000467>

Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martnell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. *New England Journal of Medicine*, 384(15), 1402–1411. <https://doi.org/10.1056/NEJMoa2032994>

Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. *Journal of Psychopharmacology*, 32(7), 725–731. <https://doi.org/10.1177/0269881118754710>

Dahl, C. J., Lutz, A., & Davidson, R. J. (2015). Reconstructing and deconstructing the self: Cognitive mechanisms in meditation practice. *Trends in Cognitive Sciences*, 19(9), 515–523. <https://doi.org/10.1016/j.tics.2015.07.001>

Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021). Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. *Journal of Psychopharmacology*, 35(4), 437–446. <https://doi.org/10.1177/0269881120967878>

Dos Santos, R. G., Bouso, J. C., Alcázar-Córcoles, M. Á., & Hallak, J. E. (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. *Expert Review of Clinical Pharmacology*, 11(9), 889–902. <https://doi.org/10.1080/17512433.2018.1511424>

Faul, F., Erdfelder, E., Lang, A. G., & Buchner, A. (2007). G\* Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behavior Research Methods*, 39(2), 175–191. <https://doi.org/10.3758/BF03193146>

Galante, J., Galante, I., Bekkers, M. J., & Gallacher, J. (2014). Effect of kindness-based meditation on health and well-being: A systematic review and meta-analysis. *Journal of Consulting and Clinical Psychology*, 82(6), 1101–1114. <https://doi.org/10.1037/a0037249>

Goldberg, S. B., Riordan, K. M., Sun, S., & Davidson, R. J. (2022). The empirical status of mindfulness-based interventions: A systematic review of 44 meta-analyses of randomized controlled trials. *Perspectives on Psychological Science*, 17(1), 108–130. <https://doi.org/10.1177/1745691620968771>

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. *Journal of Psychopharmacology*, 32(1), 49–69. <https://doi.org/10.1177/0269881117731279>

Heuschkel, K., & Kuypers, K. P. (2020). Depression, mindfulness, and psilocybin: Possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review. *Frontiers in Psychiatry*, 11, 224. <https://doi.org/10.3389/fpsy.2020.00224>

Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016). Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). *Frontiers in Human Neuroscience*, 10, 269. <https://doi.org/10.3389/fnhum.2016.00269>

Payne, J. E., Chambers, R., & Liknaitzky, P. (2021). Combining psychedelic and mindfulness interventions: Synergies to inform clinical practice. *ACS Pharmacology & Translational Science*, 4(2), 416–423. <https://doi.org/10.1021/acspsci.1c00034>

- Podsakoff, P. M., MacKenzie, S. B., & Podsakoff, N. P. (2012). Sources of method bias in social science research and recommendations on how to control it. *Annual Review of Psychology*, 63, 539–569. <https://doi.org/10.1146/annurev-psych-120710-100452>
- Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022). Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. *Journal of Psychopharmacology*, 36(1), 31–45. <https://doi.org/10.1177/02698811211066709>
- Pots, W., & Chakhssi, F. (2022). Psilocybin-assisted compassion focused therapy for depression. *Frontiers in Psychology*, 13, 812930. <https://doi.org/10.3389/fpsyg.2022.812930>
- Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. *Journal of Psychopharmacology*, 36(3), 258–272. <https://doi.org/10.1177/02698811211069100>
- Schlosser, M., Barnhofer, T., Requier, F., Deza-Araujo, Y. I., Abdoun, O., Marchant, N. L., Chételat, G., Collette, F., Klimecki, O. M., & Lutz, A. (2022). Measuring psychological mechanisms in meditation practice: Using a phenomenologically grounded classification system to develop theory-based composite scores. *Mindfulness*, 13(3), 600–614. <https://doi.org/10.1007/s12671-021-01816-0>
- Sexton, J. D., Crawford, M. S., Sweat, N. W., Varley, A., Green, E. E., & Hendricks, P. S. (2019). Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. *Journal of Psychopharmacology*, 33(9), 1058–1067. <https://doi.org/10.1177/0269881119827796>
- Simonsson, O., Fisher, S., & Martin, M. (2021a). Awareness and experience of mindfulness in Britain. *Sociological Research Online*, 26(4), 833–852. <https://doi.org/10.1177/1360780420980761>
- Simonsson, O., & Goldberg, S. B. (2022). Linkages between psychedelics and meditation in a population-based sample in the United States. *Journal of Psychoactive Drugs*, 55, 11–18. <https://doi.org/10.1080/02791072.2021.2022816>
- Simonsson, O., Martin, M., & Fisher, S. (2020). Sociodemographic characteristics and health status of mindfulness users in the United States. *Mindfulness*, 11(12), 2725–2729. <https://doi.org/10.1007/s12671-020-01486-4>
- Simonsson, O., Sexton, J. D., & Hendricks, P. S. (2021b). Associations between lifetime classic psychedelic use and markers of physical health. *Journal of Psychopharmacology*, 35(4), 447–452. <https://doi.org/10.1007/s12671-020-01486-4>
- Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., & Goldberg, S. B. (2022). Classic psychedelics, health behavior, and physical health. *Therapeutic Advances in Psychopharmacology*, 12, 20451253221135364. <https://doi.org/10.1177/20451253221135363>
- Smigielski, L., Kometer, M., Scheidegger, M., Krähenmann, R., Huber, T., & Vollenweider, F. X. (2019). Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. *Scientific Reports*, 9(1), 1–13. <https://doi.org/10.1038/s41598-019-50612-3>
- Uthaug, M. V., Van Oorsouw, K., Kuypers, K. P. C., Van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018). Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. *Psychopharmacology*, 235(10), 2979–2989. <https://doi.org/10.1007/s00213-018-4988-3>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.